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Carbohydrate supramolecular chemistry: beyond
the multivalent effect
Manuel González-Cuesta,a Carmen Ortiz Mellet *a and
José M. Garcı́a Fernández *b
It has been amply constated that sugar ligand multivalency increases lectin-binding avidities dramatically,
thereby modulating the capacity of carbohydrates to participate in supramolecular recognition
processes involving transfer of biological information. The importance of this concept, the multivalent or
glycoside cluster effect, in cell biology in general and in the glycosciences in particular is reflected in the
ever-growing number of papers in the field. An impressive range of glycoarchitectures has been
conceived to imitate the glycan coating of cells (the glycocalyx) in order to target complementary lectin
receptors. However, these models rarely address the heterogeneity and the fluidity of the densely
glycosylated cell membrane. They also disregard the impact that high-density nanosized arrangements
could have in their interactions with the whole spectrum of carbohydrate-interacting proteins, among
which glycosidases are notable representatives. For many years it has been tacitly assumed that:
(i) efficient recognition by lectins generally requires high densities of the putative primary ligand and (ii) the
mechanisms governing binding of a carbohydrate motif by a lectin or a glycosidase are totally disparate.
Notwithstanding, an increasing amount of evidence seriously questions this paradigm. First, it was shown
that secondary ‘‘innocent’’ ligands can play important roles in the recognition of heteroglycocluster
constructs by lectins through synergistic or antagonistic contributions, a phenomenon termed the
heterocluster effect. Second, the existence of multivalent effects in the inhibition of certain glycosidases by
glycomimetic- and, even more disturbing, glyco-coated architectures (multivalent enzyme inhibition) was
demonstrated. These observations call for a generalized multivalent effect governing the supramolecular
chemistry of carbohydrate or glycomimetic structures in a biological context, with (hetero)multivalency
acting as a multimodal switcher to drive the encoded information through different pathways. In this
Feature Article we review the advancements made in the last few years in our understanding of the
mechanisms underpinning the generalized multivalent effect, with an emphasis on the potential risks and
opportunities derived from (hetero)multivalency-elicited promiscuity.
Introduction
The mutual recognition of different chemical entities is a
fascinating phenomenon at the core of fundamental processes
in life. The co-assembly of viral RNA and protein capsids to
bring about functional viruses, the infection of a host cell, the
immune response and the metastasis of tumors are examples
of critical events determined by the reciprocal identification of
specific biomolecular partners in a highly complex dynamic
environment. Exquisite matching relationships are achieved
through the complementary 3D disposition of functional hot-
spots in the intervening species, enabling the establishment of
a network of noncovalent interactions that stabilizes a transient
supramolecular body. The whole sequence can be seen as a
decrypting process whereby precisely encoded information is
transferred, leading to the activation or deactivation of specific
signaling pathways. For the communication flow to occur, a
minimum time of contact between the participating ligand and
receptor units is necessary, which in turn requires reaching a
‘‘biologically useful’’ binding affinity threshold. In some cases,
this is warranted by the one-to-one complementation of the
parties leading to a ‘‘lock-and-key’’ fitting mode. A typical
example is the formation of antibody–antigen complexes. In
other cases, however, the interactions engaged in the pairing
episode are intrinsically too weak to reach effective ligand–host
dissociation constants and require an amplification contrivance.
In nature this is achieved by deploying several replicates of one or
the two components so that they can interrelate in a cooperative
manner. The system as a whole then behaves differently from
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anticipations based on the individual interactions acting in
isolation, resulting in a net increase in the lifetime of the bound
state. The accumulated strength resulting from individual affinities
performing concurrently is known as avidity, whereas the general
strategy is called multivalency.1–4
The recognition of carbohydrates by protein receptors (lectins)
relies on multivalency much more intensely than processes
implying any other type of biomolecule. Sets of glycan recognition
motifs (glycotopes) and cognate lectins possessing several carbo-
hydrate recognition domains (CRDs) have typically to play
concertedly in order to afford productive associations.5–8 In this
manner, individually weak affinities are enhanced by orders of
magnitude, an observation termed the multivalent or glycoside
cluster effect. Since its enunciation in 1995,9 the multivalent
effect has dominated carbohydrate supramolecular chemistry,
delivering not only a general principle that has led to decisive
advances in our understanding of glycobiology but also a
versatile tactic to interfere in carbohydrate-mediated processes
for fundamental studies or biomedical applications.10–13 The
advent of ‘‘click’’ chemistry and the implementation of ‘‘precision
macromolecular synthesis’’ concepts, together with the develop-
ments in nanotechnology and self-assembly, have further provided
a fantastic toolbox to sculpt the topology of glycoobjects and,
eventually, incorporate refined functional properties.14–32 Collec-
tively, this vast work has contributed to settle the assumption that
presenting a given glycotope in multiple copies on a suitable
scaffold is a safe and efficacious way to target a complementary
lectin, preserving or even enhancing binding selectivity.
While the success of the above notion is attested by many
studies, a lot of evidence questions this one-dimensional
picture. For instance, the recognition of glycans by complementary
lectins has been found to be strongly dependent on density and
architectural parameters.33–35 The biological information encoded
by carbohydrates, the ‘‘glycocode’’,36,37 does not seem to be written
in the monosaccharide sequences forming the oligosaccharide
chains, but in much more complex glycan patterns that are read by
lectins behaving as pattern recognition proteins.38,39 The hetero-
geneity and the fluidity of the densely glycosylated cell membrane,
the glycocalyx, contribute decisively to achieve the right arrangement
for a perfect multi-spot match in a precise context.40 Importantly, a
change in the glycocalyx configuration, e.g. in response to a different
cell state, can promote dissimilar recognition processes while
involving essentially the same glycotopes.41 Heterogeneity and
promiscuity in multivalent carbohydrate recognition are indeed
implicit in the glycome and play essential roles in adapting
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José M. Garcı́a Fernández
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cellular responsiveness to environmental conditions.42 The
complexity of developing suitable models and analytical tools
to investigate these phenomena and exploit them in drug design
represents a daunting challenge. Nevertheless, the last few years
have witnessed a series of discoveries that have the potential to
provoke a drastic revolution in our conceptualization of multi-
valency and convey the necessary instruments to move ahead.
First, the synthesis of topologically defined high-density hetero-
glycoclusters and their evaluation as lectin ligands revealed
unsuspected synergies between putative and non-cognate glyco-
topes. Next, a number of carbohydrate processing enzymes,
namely glycosidases and glycosyl transferases, were found to be
responsive to multivalent presentations of carbohydrate analogues
(glycomimetics) in a way somehow reminiscent of carbohydrate–
lectin recognition. Then, (hetero)multivalent glycomimetic or
glycoligand and hybrid glycomimetic/glycoligand systems capable
of triggering simultaneous recognition/inhibition of lectin/glyco-
sidase pools were reported. This new scenario prompted the
advancement of the ‘‘generalized multivalent effect’’,43 a shift in
paradigm whereby (hetero)multivalency is perceived as an action
principle with the capability to induce, deter or enhance specific
recognition phenomena towards a spectrum of lectins and carbo-
hydrate processing enzymes in a multimodal manner. In this
Feature Article we track the latest developments in this efferves-
cent field, contextualizing our own results. We purposely focus on
contributions that shed some light on the molecular basis behind
the experimental observations, supply evidence of the relevance of
the generalized multivalent effect in a biological context and
explore the new channels that it opens in glycobiology and
biomedicine. For a broader view of the state-of-the-art in carbo-
hydrate supramolecular chemistry, including biomolecular recogni-
tion, self-assembly and host–guest carbohydrate chemistry, the





Imitating the densely glycosylated cell membrane to correctly
evaluate glycan interactions and their biological consequences
has been a constant motivation for research in the field of
multivalency.52 Intuitively, the presence of a diverse ensemble of
glycotopes in heteromultivalent glycosystems has the potential
to enable simultaneous interactions with distant areas in the
same lectin, e.g. subsites hosting different monosaccharide
residues of an oligosaccharide ligand in the corresponding
supramolecular complex, or with an arrangement of lectins
with assorted specificities. The first vision was initially explored
by Kobayashi and coworkers and systematized as the ‘‘carbo-
hydrate module method’’.53–55 Basically, it consists of decon-
structing the glycan ligand whose lectin recognition properties
are to be emulated into elemental motifs that are copolymerized
together. Provided that the fragments in the side chain of the
resulting synthetic heteroglycopolymers can act cooperatively
with each other, enhanced affinities against the target lectin can
be achieved (Fig. 1).
The simplicity of the carbohydrate module method makes it
very appealing, but the successful implementation remains
challenging. It presupposes that the individual sugar moieties
in the heteroglycopolymer will bind at the sites in the target
lectin where they are found in the complex between the lectin
and the full oligosaccharide ligand that inspired the design,
giving rise to allosteric cooperativity.56 Yet, the effectiveness of
this mechanism is sometimes questionable.57 Moreover, it is
not always clear which modules in a natural glycan are essential
for protein recognition: some are directly involved in binding
and others are required for determining the right conformation.
Underestimating the latter can totally offset the enthalpic
benefit of cooperativity due to the entropic penalty associated
with linker flexibility.58,59 Recently, Zentel and coworkers60 and
Tacke and coworkers61 conveyed compelling evidence of the
potential of mimicking the selectin recognition properties of the
sialyl Lewisx (SLex) tetrasaccharide (NeuNAc-a(2–3)-Gal-b(1–4)-
[Fuc-a(1–3)]-GlcNAc) by the carbohydrate module approach for
biomedical applications. Selectins are a family of cell adhesion
molecules with an extracellular lectin domain that bind to
fucosylated and sialylated glycoproteins and play a key role in
the innate immune response.62–64 SLex is the common structure
required for binding in several natural glycoproteins that
behave as ligands of the selectins in the inflammatory cascade,
but the monovalent tetrasaccharide itself has rather low affinities
to all selectin members. The authors used a biocompatible poly(2-
hydroxypropyl)methacrylamide (PHMA) backbone to multivalently
and randomly present the fucose (Fuc), galactose (Gal) and
neuraminic acid (NeuAc) substructures, bearing or not a sulfated
tyramide sidechain to account for sulfation of some natural
selectin glycoprotein ligands at tyrosine residues (Fig. 2). Both
heteroglycopolymers behaved as selectin binders in vitro in
different cells.60 Additionally, the latter heteroglycopolymer
strongly bound to resident liver macrophages in vivo (mice)
and meaningfully inhibited toxic liver injury and reduced the
injury in a model of immune-mediated hepatitis.61
Heteromultivalent prototypes having the crucial glycotopes
prearranged in segregated domains are expected to be better
suited to simultaneously target lectins differing in their sugar
selectivities. This concept has been probed by the groups of
Roy and coworkers and Renaudet and coworkers with Janus65
Fig. 1 Schematic representation of the carbohydrate module method for
the preparation of heteroglycopolymers mimicking oligosaccharide lectin
ligands devised by Kobayashi and coworkers. The elemental oligosaccharide
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(Fig. 3A) and heterolayered hybrid glycodendrimers66 (Fig. 3B) or
regioselectively addressable functionalized template (RAFT) cyclo-
peptide scaffolded heteroglycoclusters (Fig. 3C),67,68 respectively.
Multiconjugates combining sugar head groups optimized for the
Pseudomonas aeruginosa (P. aeruginosa) lectins LecA and LecB
(namely Gal and Fuc) or LecA and concanavalin A (ConA), a
model mannose (Man)-binding lectin used throughout many
fundamental studies, were synthesized and evaluated. Differently
from the carbohydrate module approach, multidomain hetero-
geneous prototypes are intended to achieve multispecificity,
which may be delicate if the target lectins have different require-
ments in terms of the optimal valency or architecture of their
ligands. For instance, the formation of a complex between the
Janus heterovalent glycodendrimer in Fig. 3A and LecB was much
more complete than that formed with LecA, likely due to the higher
affinity of the fucoside residues towards LecB in comparison to that
of the galactoside residues towards LecA.65 Increasing the Gal
glycotope valency or density, as in the heteromultivalent systems
depicted in Fig. 3B and C,66,67 led to increased LecB affinities.
Considering that LecB is much less sensitive to multivalency than
LecA, Nierengarten and coworkers proposed a more sophisticated
design where ten Gal units are attached at the two rims of a
pillar[5]ene platform and two Fuc residues are located as
stoppers in a rotaxanated axle.69 The authors demonstrated that
such a ‘‘supermolecule’’ can indeed achieve high binding
affinities towards the two lectins (Fig. 3D).
LecA and LecB are particularly interesting targets from the
biomedical point of view since both are involved in the recognition,
adhesion and internalization of P. aeruginosa by airway epithelial
cells.70,71 During the initial phase of infection, multiple types of
glycans on the cell surfaces bind diverse types of lectins on the
bacteria. This heterovalent network of carbohydrate–protein inter-
actions is also critical for biofilm development and stabilization.72
Recently, Zhang and coworkers developed heteromultivalent
nanotherapeutics inspired by this natural strengthening
mechanism for the carbohydrate–lectin interactions between
the bacteria and the cells. Gold nanorods (AuNRs) decorated
with lactose (Lac) and Fuc homoglycopolymers specifically
blocked LecA and LecB, promoted bacterial aggregation and
inhibited biofilm formation.73 The near-infrared (NIR)-light-
induced photothermal effect of the AuNRs additionally endowed
the system with bacterial killing properties (Fig. 4A). The authors
further extended this biomimetic approach to the co-assembly
of polymers combining galactosylated and fucosylated blocks
together with an acid-sensitive block that switched from hydro-
phobic to hydrophilic upon protonation.74 The resulting micelles
with a heteroglycomultivalent shell specifically recognized
P. aeruginosa, inhibited biofilm formation, protected native
cells from bacterial infection and selectively released photo-
therapeutic agents included in their hydrophobic core in an
acidic microenvironment at the infection site (Fig. 4B). Notably,
the AuNRs and the co-assembled micelles coated with only the
Lac, Gal or Fuc homopolymers showed much lower biofilm
inhibition and bacterial killing properties, indicating the necessity
of heteromultivalency to achieve a synergistic effect.
Fig. 2 Structure of the sialyl Lewisx (SLex) tetrasaccharide and schematic
representation of the heteroglycopolymers conceived by Zentel and
coworkers60 and Tacke and coworkers61 to emulate the SLex selectin
binding capabilities.
Fig. 3 Representative structures of the different multidomain-type het-
eromultivalent prototypes synthesized by Roy and coworkers66 (A and B),
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In some cases, it was found that targeting different lectins
simultaneously with heteromultivalent glycoconjugates could
be achieved with no explicit phase separation of the distinct
glycotopes.75 In a very instructive study, Jiang and coworkers
prepared glycopolymeric micelles from a-Man- and b-Gal-modified
aliphatic polyesters, individually as well as in admixtures, or from
a mixed a-Man/b-Gal-modified heteroglycopolymer analog.76 The
purpose of the work was to investigate their interactions with
the macrophage mannose receptor (MMR; CD206) and the
macrophage galactose-binding lectin (MGL; CD301), both of
which mediate clathrin-dependent endocytosis. Unexpectedly,
the results showed that the nanoparticles built from the a-Man/
b-Gal heteroglycopolymer were internalized by RAW 264.7
macrophages much more efficiently than not only the nano-
particles containing a single kind of monosaccharide, but also
the nanoparticles combining the a-Man- and b-Gal glycotopes in
separate polymers, even though the relative a-Man/b-Gal ratios
were identical (Fig. 5). The same trend was observed for the
affinity towards the plant lectins ConA (a-Man specific) and
peanut agglutinin (PNA, b-Gal specific) by isothermal titration
microcalorimetry (ITC). The authors speculated that the unlike
polymer chains tend to aggregate separately, forming individual
domains at the surfaces of the nanoparticles that make it less
favorable for the establishment of concurrent interactions with
MMR and MGL receptors at the cell membrane.
The carbohydrate module method and the multidomain
approaches claim that the observed lectin binding capability
enhancements in heteromultivalent systems arise from the
synchronized action of two or more discrete supramolecular
events that can either be confined in a reduced binding site or
expand on a larger 3D contacting area. In 2005, Garcı́a Fernández,
Ortiz Mellet and coworkers reported that high-density hetero-
clusters with alternating a-Man and b-Glc residues, built on a
b-cyclodextrin (bCD) platform, exhibited ConA binding affinity
enhancements that could not be rationalized on such grounds
(Fig. 6).77 In their initial work, horseradish peroxidase-labelled
ConA (HRP-ConA) was used for enzyme-linked lectin assay
(ELLA)78–81 and ITC determinations. Although at the neutral
pH of the experiments ConA is a homotetramer, the presence of
the high molecular weight HRP label prevents cross-linking
phenomena and essentially reduces the possibilities to the 1 : 1
binding mode. The a-Man motif is a weak HRP-ConA ligand in
monovalent form but multivalent presentations can show very
high avidities. On the other hand, monovalent b-Glc is not a
ligand for ConA and only in a few cases measurable affinities
for multivalent b-Glc arrays have been reported.82–86 In hetero-
multivalent a-Man/b-Glc conjugates, however, the presence of
the b-Glc motif reinforced binding quite significantly. Thermo-
dynamic data revealed that the free energy of binding decrease,
as compared to homovalent a-Man clusters, had an entropic
origin. This led the authors to propose that the presence of a
very low affinity ligand facilitates ligand exchange processes,
resulting in a higher contribution of the ‘‘memory-like’’ rebinding
and sliding mechanisms to the multivalent effect (Fig. 6). The
overall result can be interpreted as the enhancement of the affinity
of a lectin towards a primary glycoligand by the presence of a low
affinity secondary ligand or, alternatively, as the activation of the
recognition of a secondary ligand enabled by the presence of a low
proportion of a primary ligand. The term ‘‘heteromultivalent or
heterocluster effect’’ was coined to refer to this new facet of
multivalency.77,87
The heteromultivalent effect as expressed above implies
synergistic phenomena influencing not only glycoligand–lectin
binding affinity but also selectivity, and shows in heterogly-
coclusters merging cognate and non-cognate glycotopes without
phase separation. Its occurrence has been further corroborated
Fig. 4 Schematic representation of the heteromultivalent nanotherapeutics
based on gold nanorods decorated with Gal and Fuc glycopolymers devel-
oped by Zhang and coworkers (A).73 Inhibition of bacterial biofilm formation
by using the acid-sensitive micelles that encapsulate a phototherapeutic
reported by the same group (B).74
Fig. 5 Schematic representation of the interactions of the macrophage
mannose receptor (MMR; CD206) and the macrophage galactose-binding
lectin (MGL; CD301) with nanoparticles self-assembled from a-Man (M)
and b-Gal (G) glycopolymers or from heteroglycopolymers combining
a-Man and b-Gal glycotopes and the consequences in the cell uptake rate
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in several laboratories with model ‘‘shuffled’’ heterovalent
systems built on a variety of scaffolds. Thus, Garcı́a Fernández
and Ortiz Mellet made full use of the opportunities offered by
bCD for selective functionalization to generate heteroglycocluster
diversity;88,89 Hartmann,90–92 Kikkeri93 and Chen94 synthesized
heteroglycosylated sequence-controlled oligopeptides, oligo-
amides and polymers, respectively, and Liu and Deng95 engineered
heteroglyco-gold nanoparticles. Importantly, the heteromultivalent
effect was found to be strongly dependent on the total ligand
density. As a general rule, it is not apparent in the case of low
valency heteroglycoconjugates,87,96–101 but manifests in heavily
glycosylated architectures.
Interestingly, lectins that exhibit similar affinities for the
same putative carbohydrate motif can significantly differ in their
response to heteromultivalency when this motif is exposed con-
jointly with additional weakly binding or nonbinding glycans. As a
corollary, heterogeneous glycan patterns have the potential to
enhance lectin discrimination capabilities by virtue of the hetero-
multivalent effect in a more finely tuned manner than homo-
geneously glycosylated coatings do. This concept has been
implemented by Gibson and coworkers102,103 and Kikkeri and
coworkers104 for the development of analytical devices based on
microarrays or gold nanoparticle glycotechnologies. For instance,
the Man-binding lectins ConA, human Dendritic Cell-Specific Inter-
cellular adhesion molecule-3-Grabbing Non-integrin (CD-SIGN) and
mouse Specific Intracellular adhesion molecule-3 Grabbing Non-
integrin homolog-Related 3 C-type lectins (SIGNR3) and Macro-
phage inducible Ca2+-dependent lectin receptor (Mincle) and the
Gal-binding lectins PNA, Galanthus nivalis lectin (GNL), mouse
Macrophage Galactose-type Lectin-1 (MGL1) and human galectins
1 (Gal-1) and 3 (Gal-3) showed fully different recognition patterns
when profiled against a battery of microarrays printed from homo-
and heterotrivalent dendrons combining Man, a(1–2)-mannobiose,
a(1–2)-mannotriose and Gal, as depicted in Fig. 7.104
Tanaka and coworkers further demonstrated that glycohetero-
geneity affects the fate of glycocoated nanoconstructs in vivo by
promoting differential interactions with protein receptor partners
expressed in specific cells, tissues or organs.105–110 Thus, the
arrangement of glycans relative to one another in a diverse series
of structurally well-defined heteroglycoalbumins critically influenced
pathway-selective excretion (urinary or gall bladder) or cell-specific
targeting, thereby impacting biodistribution or tumor adhesion
(Fig. 8). Their results open new avenues for the development of
glycan-based imaging or therapeutic tracers.
The relevance of the heterocluster effect in cell biology was
presumed since its formulation fifteen years ago on the basis of
model glycocluster–lectin recognition studies.77,87 However,
direct experimental evidence and theoretical support have been
provided only very recently. The contribution by Wu and coworkers
has been fundamental in this line. In their seminal work,111,112
Fig. 6 Schematic representation of the rebinding and sliding mechanisms
in the interaction of heteromultivalent a-Man/b-Glc bCD-centered hetero-
glycoclusters with the a-Man-specific lectin ConA as discussed by Garcı́a
Fernández and coworkers.77,88,89 Upon initial binding of the putative Man
glycotope, the secondary Glc residues can transiently bind to the carbo-
hydrate recognition domains in the lectin and entropically favor both
processes, enhancing the lifetime of the bound state.
Fig. 7 Structures of the homo- and heteroglycodendrons used by Kikkeri
and coworkers to implement a microarray-based platform for lectin sensing
based on the heteromultivalent effect. The ensembles of Man- and Gal
binding lectins framed in green and yellow, respectively, were used to provide
a proof of concept (see the text for the full forms of the abbreviations/
acronyms used).
Fig. 8 Differential cancer cell binding properties and in vivo tumor
adhesion capabilities of heterogeneous-clustered glycoalbumins as
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the authors spotlighted unexplained data by Yanasigawa and
coworkers,113 signalling that binding of cholera toxin B subunit
(CTB) homopentamers to mouse embryonic neural precursor
cells does not correlate with GM1 ganglioside (Gal-b-(1–3)-
GalNAc-b-(1–4)[Neu5Ac-a-(2–3)]Gal-b-(1–4)-Glc-Ceramide) expression,
even though GM1 is well known to be the primary ligand of the
toxin. They also noted reports by Klassen and coworkers114–116
postulating cooperative effects in the binding of CTB to GM1. Most
strikingly, the authors demonstrated that the GM2 ganglioside
(GalNAc-b-(1–4)[Neu5Ac-a-(2–3)]Gal-b-(1–4)-Glc-Ceramide), which
is a very weak ligand of the toxin, can contribute to CTB binding
if present in a glycolipid mixture with a high affinity binder
such as GM1 (Fig. 9).112 The experimental observations cannot
be explained on the basis of allosteric regulation, but they
are undoubtedly dynamic in nature and associated with the
simultaneous presence of the high and low affinity ligands over
a certain expression level in a relatively large peripheral area. The
fact that going from the bulk to coating is a necessary requisite
led the authors hypothesize that the heterocluster effect is
mediated by a simple mechanism: reduction of dimensionality
(RD). The basis of RD is that once the lectin has attached to a
strong receptor in a fluid membrane, subsequent binding events
are confined to a 2D surface. Surface binding rates can then be
increased up to 1014 as compared with bulk binding rates, so that
even a weak ligand, such as GM2 for CTB, can now participate in
next binding events.
Through RD, heteromultivalency can significantly alter lectin
binding properties, including avidities, selectivities and kinetics,
offering a new strategy to design high-affinity carriers for targeted
drug delivery.117–120 As a proof of concept, Wu and coworkers
demonstrated that the retention of liposomes by the pathogenic
bacteria Pseudomonas aeruginosa was significantly enhanced when
the strong LecA binder globotriaosylceramide (Gb3; Gal-a-(1–4)-
Gal-b-(1–4)-Glc-Ceramide) was combined with lactosyl-ceramide or
Gal-b-ceramide, which are much weaker LecA ligands, as com-
pared with liposomes with a homogeneous array of Gb3.120
Heteromultivalent cooperative phenomena under RD also provide
a rationale for the fact that human intestinal epithelial cells or
murine lung cells are efficiently infected by the bacteria in spite of
expressing Gb3 at very low levels.121,122
Kinetic Monte Carlo (kMC) simulations supported the under-
pinning role of RD in the heterocluster effect.123 The main
conclusions of the kMC computational study are in full agreement
with the experimental observations, namely: (a) the density of the
low affinity ligand is a critical parameter for the activation of the
heterocluster effect and a threshold density is needed to enable its
contribution to lectin binding, (b) a tiny amount of high affinity
ligand is sufficient to accelerate lectin binding to low affinity
ligands and (c) heteromultivalent binding phenomena can modulate
lectin binding kinetics and lectin bound states via ligand exchange
processes on the surface. Note that ligand exchange under RD is
equivalent to the entropy-driven mechanism hypothesized for
high-density nanosized heteroglycoclusters.77,87 In conjunction
with results reported by other laboratories on biologically
relevant lectins binding to heteromultivalent systems,124–126
the ensemble of evidence establishes that heteromultivalency
plays a key role in lectin–glycan recognition and that cells
probably utilize this mechanism to regulate the downstream
of lectin functions.
Multivalent glycosidase inhibition
Enzymatic substrate processing is generally considered to be
preceded by a typical lock-and-key supramolecular recognition
event that warrants enzyme specificity. In the case of a glyco-
sidase (glycosyl hydrolase) the substrate is a glycoside that must
reach the catalytic receptacle and fit the configurational and
conformational requirements imposed by the architecture of
the active site. In most cases, a rather strict complementarity
between the glycone substitution pattern and the amino acids
at the glycone hosting spot (the so-called 1 site) is achieved
through an intricate network of hydrogen bonding, stacking and
hydrophobic contacts. This matching relationship is mandatory
for the glycoside to adopt the right conformation in the corres-
ponding enzyme:substrate complex and the subsequent activation
of the catalytic machinery. Contributions to binding from the
aglycone moiety at the aglycone (+1) binding site are commonly
less vital, although the aglycone nature can significantly affect the
catalytic reaction rate or even impede enzymatic hydrolysis by steric
and/or conformational biases, which can also be exploited in the
design of enzyme regulators.127–129
The ambition of reproducing the biunivocal enzyme–sub-
strate relationship has monopolized the search for glycosidase
inhibitors for biological studies or biomedical applications. Not
surprisingly, the iconic specimens are monomeric glycomimetics
with hydroxylation profiles of structural complementarity with the
glycone moiety of the natural substrate, among which the
nitrogen-in-the-ring monosaccharide analogues of the iminosugar
category are by far the most popular.130 Appropriately selected
iminosugars, either from natural origin or chemically synthesized,
enable altering the cellular glycosylation profile, interfering in the
Fig. 9 Schematic representation of the reduction of dimensionality (RD)
concept in the binding of cholera toxin B subunit (CTB) homopentamers to
GM1 (high-affinity ligand) and GM2 (low-affinity ligand) in the cell
membrane as reported by Wu and coworkers.111,112 f1 and f2 are the
binding rates of GM1 and GM2 to CTB in the bulk and on the surface,
respectively. After a lectin has attached to a high-affinity ligand, a low-
affinity ligand encounters the bound lectin, completing the heteromulti-
valent binding (f2 4 f1). In a next step, the lectin can be stabilized by two
low-affinity ligands (not shown) and the free high-affinity ligand can then
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metabolism of glycoconjugates and carbohydrates, modifying the
carbohydrate-dependent properties of glycoproteins or hindering
the carbohydrate-mediated interaction of host cells with infective
agents, among others.131 Defying the prevalent philosophy,
Gouin and coworkers advanced in 2009 the visionary idea that
glycosidases might be responsive to multivalent arrangements
of inhibitory motifs (inhitopes) in the same manner as lectins
having a single CRD available are sensitive to multivalent arrays
of carbohydrate ligands, provided that the kinetic and thermo-
dynamic parameters of the individual binding phenomena are
apt.132 The merit of their work is double: first, a potential
analogy between carbohydrate/lectin and glycomimetic/glycosidase
supramolecular binding mechanisms has been invoked for the first
time; secondly, by testing a trivalent conjugate of the iminosugar
1-deoxynojirimycin (DNJ), a piperidine analogue of D-gluco-
pyranose, towards a panel of glycosyl hydrolases, they determined
a 2.6-fold enhancement in the inhibitory potency towards Jack
bean a-mannosidase (JbMan) on a DNJ molar basis (Fig. 10A).
Although significant, the above multivalent enzyme inhibition
(MEI) effect is moderate and Gouin’s work would have had
probably passed overlooked if one year later Compain, Ortiz
Mellet, and Nierengarten had not published that the inhibitory
potency of DNJ towards JbMan was boosted up to 179-fold on a
DNJ molar basis when the inhitope was exposed in 12 copies on
a C60 fullerene scaffold (Fig. 10B).
133 This was a counterintuitive
aftermath that advanced multivalency as a promising tool for the
design of potent glycosidase inhibitors and encouraged to visualize
MEI as a variant of the glycoside cluster effect. MEI soon became a
trending topic in the glycosciences that has been discussed in
several reviews.43,134–139 A consistent body of work from the four
mentioned laboratories as well as by the groups of Cardona,
Moreno-Vargas, Blériot and Li, often in multicollaborative net-
works, confirmed the reactiveness of JbMan and other glycosidases,
such as a- and b-glucosidase, amyloglucosidase or hexosaminidases,
to multivalent arrays of iminosugars.140–162 In addition to poly-
hydroxylated pyrimidine-type iminosugars like DNJ, imino-
sugars with other azaheterocyclic cores, e.g. pyrrolizidine,145,147
pyrrolidine157,158,160 or azepane156 derivatives, also proved com-
petent to elicit MEI when conjugated to multi-armed platforms.
A strong dependency of the inhibition potency enhancement
elicited by multivalency from the total valency and architectural
parameters was documented. Yet, only in the case of JbMan a
parallelism with the behavior generally observed in carbo-
hydrate–protein interactions could be supported throughout
the different studies.
JbMan and other a-mannosidases of the glycosyl hydrolase
(GH) family GH38 exhibit a rather open and accessible active
site and often are multimeric in their functional form, a scenario
that is reminiscent of that encountered in lectins. Thus, JbMan
itself is a dimer of heterodimers, with each of the heterodimers
possessing a catalytic receptacle. It seemed therefore logical to
assume that it can share with lectins the same mechanisms
leading to high avidities when faced to clustered ligand partners,
that is, the sliding and rebinding processes associated with high
local epitope density and the crosslinking and chelation pheno-
mena characteristic of multipoint interactions.43 Indeed, experi-
mental evidence for co-aggregation events involving multivalent
iminosugar constructs and JbMan has been obtained by
atomic force microscopy (AFM), transmission electron microscopy
(TEM), mass spectrometry and analytical ultracentrifugation
measurements.143,152,157 Recently, Compain and coworkers
further obtained the first high-resolution crystal structures of
apo JbMan and of its complex with a 36-valent DNJ-cyclopeptoid
conjugate that displayed the largest inhibition enhancement
observed for this enzyme so far (Fig. 10C and D).163 The data
clearly demonstrated the interplay of bridging and chelation
processes in the formation of a 2 : 1 JbMan:multivalent inhibitor
sandwich-type complex, with all four glycone sites occupied by
DNJ subunits.
Differently from JbMan, other glycosidases reported to experi-
ence MEI are monomeric and/or have buried catalytic sites, which
are hardly compatible with the carbohydrate–lectin affinity
enhancement-like mechanisms sustained for the former. Notably,
in some cases multivalency switched on, rather than enhanced,
the inhibitory capacity of a glycomimetic towards a glycosidase
while simultaneously up- or down-regulating the inhibitory activity
against others. To reconcile the experimental observations, Garcı́a
Fernández, Nierengarten, Ortiz Mellet and coworkers launched
Fig. 10 Structures, Jack bean a-mannosidase (JbMan) inhibition constant
(Ki) values and normalized relative inhibition potencies (rp/n; DNJ molar
basis) of the trivalent (A), dodecavalent (B) and 36-valent (C) DNJ conjugates
reported by Gouin and coworkers;132 Compain, Ortiz Mellet, Nierengarten
and coworkers (B)133 and Compain and coworkers.139 A schematic
representation of the complex of the latter with JbMan, based on the
reported crystal structure,163 showing two heterodimeric enzyme units
with the four catalytic sites (highlighted in pink) occupied by DNJ
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the hypothesis that multimerization of a glycomimetic onto a
nanometric scaffold elicits binding modes to the glycosidases
that can be radically different from the binding mode of the
monomer.164 The authors capitalized on the unique stereoelectronic
and chemical properties of the so-called sp2-iminosugar
glycomimetics,165 in which the underlining amine group of
iminosugars is replaced into a trigonal planar pseudoamide-
type nitrogen (N-carbonyl, N-thiocarbonyl, N-imino group), with
a substantial sp2-hybridization nature (e.g., as in carbamate,166
thiocarbamate,167–169 urea,170–172 thiourea,173–180 isourea,180–187
isothiourea,187–195 guanidine,196,197 sulfamide198 or thiohydantoin199
functionalities), to access stable O-, S-, N- and C-pseudo-
glycosides.200–211 Through click-type multiconjugation strategies,
they then succeeded in preparing homogeneous multivalent
glycoside analogues on a fullerene C60 scaffold that exhibited
dual recognition capabilities towards lectins and glycosidases.164
A competitive lectin–glycosidase binding assay was next imple-
mented that enabled mapping the enzyme regions interacting with
the high-valency sp2-iminosugar conjugates. Briefly, it consists of
determining the effects of reference inhibitors of the enzyme known
to bind at glycone, glycone/aglycone or surface binding sites in the
steady-state partition of the multivalent inhibitor between the lectin,
labelled with horseradish peroxidase (HRP; reporter enzyme), and
the glycosidase. If the reference inhibitor and the multivalent ligand
under study compete for the same site in the glycosidase, the
capability of the enzyme to sequester the ligand will lessen in the
presence of the former (Fig. 11). By using this technique, JbMan/
multivalent enzyme inhibitor complex formation was found to
involve substantial implications for the glycone site, which is in
agreement with the reported crystal structure.163 In sharp con-
trast, in the case of the a-glucosidase from Saccharomyces
cerevisiae (yeast maltase; GH13) the multivalent derivatives bind
at low affinity non-glycone binding sites of the enzyme, leading
to inhibition by a ‘‘recognition and blockage’’ mechanism.
This operational model likely applies also to the isomaltase
(Saccharomyces cerevisiae), b-glucosidase (bovine liver), and
a-galactosidase (green coffee beans) enzymes, all of them belonging
to glycosyl hydrolase families known to possess relatively deep
catalytic sites (GH13, GH1, and GH27, respectively).164
The monovalent/multivalent shift in preferred binding mode
supported by the above data provides an immediate explanation
for the multivalency-dependent ‘‘on–off’’ switching effect observed
for some inhitope-glycosidase pairs. It may happen, for instance,
that a monovalent inhitope does not match the glycone site but is
able to bind at aglycone and/or surface sites, thus benefitting from
multivalency when exposed in a multicopy manner and eventually
impairing the access of the substrate to the catalytic locus.
Alternatively, it is conceivable that upon binding at secondary
surface binding sites the multivalent ligand could stabilize
enzyme conformations facilitating, instead of hampering, sub-
strate processing, in the same manner as some polysaccharides act
as enhancers of amylases.212 This reasoning provides a reliable
explanation for the apparently contradictory observation by Gouin
and coworkers on dextran-based DNJ and 1-deoxymannojirimycin
(DMJ) polymers, with valencies ranging from 20 to 900, behaving
as activators of several glycosidases (two galactosidases, a
fucosidase and a bacterial mannoside phosphorylase).213
As already demonstrated for classical monovalent inhibitors,
MEI offers the possibility of developing glycosidase ligands that
stabilize the proper folding of disease-causative misfolded
mutant forms of the enzyme, a therapeutic paradigm termed
pharmacological chaperone therapy.214,215 This concept has already
been demonstrated by Compain and coworkers for Gaucher disease,
an autosomal recessive lysosomal storage disorder (LSD) due to
b-glucocerebrosidase (GCase) dysfunction,216–218 and by Higaki,
Garcı́a Fernández, Ortiz Mellet and coworkers for a-mannosidosis,
another LSD involving malfunctioning of lysosomal a-mannosidase
(LAMAN).219 Compain and coworkers also reported a beneficial
effect of multivalent DNJ derivatives in cystic fibrosis by rescuing the
misfolded mutant cystic fibrosis transmembrane conductance
regulator (CFTR) protein from endoplasmic reticulum-associated
degradation (ERAD) in patient cells.220 The results are compatible
with a calnexin-dependent mechanism of action, but not with the
inhibition of ER a-glucosidases I and II as is the case for monovalent
DNJ derivatives.
Nguyen and coworkers221,222 used computational studies to
implement a non-iminosugar-based strategy for MEI-mediated
selective inhibition of heparanase, a b-endoglucuronidase whose
main function is cleaving the internal b-(1–4) glycosidic bond
between glucuronic acid (GlcA) and N-sulfated glucosamine
(GlcNS) along heparan sulfate (HS) chains in proteoglycans in
the extracellular matrix. The authors first identified the disulfated
(at the N0- and 60-O-positions) disaccharide GlcNS(6S)a-(1–4)GlcA
as the preferred unit for supramolecular binding at the 2 and1
Fig. 11 Schematic representation of the lectin–glycosidase competitive
binding assay developed by Ortiz Mellet, Garcı́a Fernández and coworkers
to map the binding mode involved in multivalent enzyme inhibition (MEI). The
assay construction further implies a non-labelled lectin fixed to the surfaces of
microplate wells, thereby enabling quantification of the effect of the reference
glycosidase inhibitors in the lectin crosslinking capabilities of the probed
compound. The data can be directly correlated with the displacement of
the equilibrium between the lectin–multivalent inhibitor complex and the
glycosidase–multivalent inhibitor complex. Note that the choice of reference
inhibitor depends on the glycosidase under study. The structures depicted
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glycone binding sites. They next designed glycopolymers exposing
this component for maximal heparanase inhibition and minimal
anticoagulant activity, from which a 12-valent representative was
determined to be the most potent heparanase inhibitor with a
picomolar inhibitory concentration (meaning an over 1000-fold
enhancement as compared with the monovalent control) and tight
binding characteristics. This is notable because heparanase is a
monomeric enzyme with a hindered active site. While the molecular
basis for MEI is not discussed, it is interesting to speculate that the
dissociation rate of the disaccharide motif, which is indeed the
same present in the reaction product of enzymatic hydrolysis of HS,
must be fast enough to allow rebinding processes to operate, as far
as the spacers and ligand densities are adjusted to prevent steric
clashes. The main motivation for this research is that HS degrada-
tion by heparanase in the extracellular matrix has been correlated
with tumor angiogenesis and metastasis. Rewardingly, the authors
found that the optimal glycopolymers showed potent antimetastatic
effects against 4T1 mammary carcinoma cells and inhibited
experimental metastasis into the lungs in vivo (Fig. 12).223 MEI
was also invoked by Nishimura and coworkers to account for the
efficiency of nanosomes exposing b-linked N-acetylglucosamine
(GlcNAc) suicide substrates at inhibiting the lysosomal b-hexo-
saminidases and triggering apoptosis in cancer cells as well as
in a mouse model, although the underlying molecular mechanism
remains unclear.224
Multivalency-promoted lectin/glycosidase cross-talk behaviours
The conclusion that multivalent glycomimetics can alter glycosidase
functioning upon binding in lectin-like regions beyond the catalytic
area led to the conjecture that glycotope-related versions might
behave similarly. In other words, multivalency might turn a putative
glycosidase substrate, a glycoside, into an inhibitor by eliciting
‘‘aberrant’’ supramolecular binding modes.164 Confirmation of this
hypothesis was provided in 2015 by Siriwardena, Garcı́a Fernández,
Ortiz Mellet, Szunerits and coworkers after evaluating glycocoated
nanodiamonds (NDs) against a panel of commercial glycosidases
(Fig. 13).225 The authors found that a-O-glucosides and also
a-O-mannosides, when conjugated on ND particles, were not only
resistant towards the hydrolytic action of the corresponding
matching glycosidases, but acquired the ability to inhibit them.
Moreover, the glycocoated NDs further became inhibitors of
mismatching enzymes for which they do not serve as substrates
even when in their monovalent form. A step ahead, it was
established that glycosidase inhibition was sensitive to hetero-
geneous arrangements of the Glc and Man motifs in the same
manner as the binding affinity to ConA lectin was. For instance,
homoglucosylated-NDs (Glc-NDs) and homomannosylated-NDs
(Man-NDs) inhibited S. cerevisiae a-glucosidase with inhibition
constant (Ki) values of 22 and 9.4 mM, respectively, whereas Glc/
Man-NDs (Glc : Man 1 : 1) with identical total saccharide loadings
were about 5-fold more potent inhibitors of this enzyme (Ki 1.9 mM).
Conversely, inhibition of E. coli b-galactosidase by Glc-NDs
(Ki 1.9 mM) and Man-NDs (Ki 13.2 mM) was thwarted when both
glycotopes were exposed together in Glc/Man-NDs (Ki 268 mM).
In other words, the supramolecular events underlining multi-
valent enzyme inhibition for a given inhibitory motif/enzyme
pair can be significantly altered by the presence of a second
partner, leading to positive or negative synergies, what represents an
extension of the heterocluster effect.
Additional evidence for enzyme inhibition by multivalent
glycosystems has been provided using glycofullerenes226 and
glycocyclodextrin conjugates.227,228 Integrated mechanistic studies
exploiting ELLA and lectin/glycosidase competitive assays were
conducted for homogeneous constructs as well as for mixed glyco-
side/glycomimetic (sp2-iminosugar) heterovalent arrays.226,227
Collectively, the ensemble of results substantiates the vision
that multivalent presentations of a glycotope or an inhitope can
promote binding modes to glycosidases that show significant
analogies to those governing carbohydrate–lectin supramolecular
interactions. Multivalent arrays can thus simultaneously act on
lectins and glycosidases in a multimodal manner. Moreover, a
given glycotope or inhitope moiety may elicit different responses
depending on the presence or absence of a second glyco(mimetic)
motif, even if a priori irrelevant towards the lectin/glycosidase
target, supporting a unified framework for the glycoside cluster
effect, the heteromultivalent effect and multivalent enzyme
inhibition: the generalized multivalent effect.43 By changing
the total and partial valencies and adjusting the overall topology
Fig. 12 Structures of the heparansulfate (HS) region where heparanase
acts and of the multivalent glycopolymer prepared by Tanaka and
coworkers225 exposing the GlcNS(6S)a-(1–4)GlcA disaccharide, devoid of
the scissile bond, to achieve potent heparanase inhibition.
Fig. 13 Schematic representation of the Glc/Man heterovalent glyconano-
diamonds exhibiting simultaneous lectin binding and glycosidase inhibition
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of the (hetero)multivalent construct, ‘‘on’’ or ‘‘off’’ statuses for a
range of lectins and glycosidases can be triggered, markedly
altering the selectivity profile encountered for monovalent
derivatives.
The shift in the perception of multivalency, from a natural
and safe strategy to achieve useful responses in carbohydrate-
mediated supramolecular processes to a multichannel switcher
with the potential to act on a range of receptor/enzyme recognition
events, depicts a much more complex scenario than classically
assumed. On the one hand, the generalized multivalent effect
calls for a careful evaluation of the potential risks derived from
multivalency-associated ‘‘biological messiness’’,229 expanding
from carbohydrate receptors to glycoprocessing enzymes. On
the other hand, the new evidence also informs the possibility of
taking advantage of multivalency to finely shape the supra-
molecular properties of carbohydrates in an intrinsically multi-
factorial biological context. It is conceivable, for instance, that
purposely tailoring glycoligands to specifically interact with bio-
medically relevant lectin/glycosidase subsets opens new channels
in multitargeted drug design. Garcı́a Fernández, Renaudet and
Ortiz Mellet have recently implemented this notion in the
development of mannosyl-coated glycoclusters with the ability
to simultaneously and distinctly target the macrophage mannose
receptor and lysosomal storage disorder-associated lysosomal
glycosidases.230 After screening a series of structurally diverse
candidates, the authors encountered that the MMR avidity, as
determined by a modified ELLA protocol,231,232 was essentially
dependent on the total Man valency. In contrast, glycosidase
selectivity was strongly reliant on the overall glycoarchitecture
topology: a heptavalent b-cyclodextrin conjugate (Fig. 14, upper
pathway) behaved as a selective inhibitor of b-glucocerebrosidase
(IC50 0.1 mM), whereas a hexadecavalent RAFT cyclopeptide
derivative (Fig. 14, lower pathway) turned to be a highly selective
inhibitor of lysosomal a-mannosidase. Since binding to the
MMR inherently elicits macrophage uptake, these compounds
epitomize the first examples of intrinsically site-specific, self-
deliverable glycosidase regulators.
Conclusions and future outlook
Pioneering work in 1999 by Kahne and coworkers already
described that lectin specificity could be altered in heterovalent
as compared with homovalent glycosurfaces.233 Ten years later,
Penadés and coworkers reported that lactoside substituents
became resistant to the action of b-galactosidase when multi-
valently exposed at the periphery of micelles or gold nanoparticles
while retaining the ability to bind the galactose-specific agglutinin
from Viscum album.234 The authors speculated that b-galactosidase
recognition probably occurred, but that binding of a first enzyme
molecule to the multivalent conjugate reduces the accessibility of
other lactose residues to new enzyme molecules. These early
manifestations of the heteromultivalent effect and multivalent
enzyme inhibition have been largely supported by an increasing
number of publications highlighting the relevance of those
phenomena, not only in model systems but also in a biological
context. The last few years have witnessed crucial advances in
our understanding of multivalency-induced carbohydrate recogni-
tion promiscuity under the new generalized multivalent effect
paradigm. Yet, much work is still needed to unveil the precise
mechanisms at play; this is critical both to prevent potential risks
and to program specific activities.
The increasing awareness of the multilateral character of
(hetero)multivalency, with additional reports expanding the
range of MEI responsive glycosidases235,236 and extending the
generalized multivalent effect to the glycosyltransferase enzyme
category237–239 and anti-carbohydrate antigen antibodies,240
will likely fuel research in carbohydrate supramolecular chemistry
with a new perspective. The current embodiments exploiting the
heteromultivalent effect to reach optimal cell targeting in vivo76
and multivalent inhibitors to regulate the activity of disease-
associated enzymes, e.g. in the context of LSDs,216–219 cystic
fibrosis220 or cancer,225 pave the way for future developments.
The possibility of combining enhanced glycoreceptor capabilities
and specific glycosidase inhibitory properties in designing multi-
targeted glycodrug prototypes is particularly appealing in this
sense. Glycoclusters targeting the MMR and LSD-causative glyco-
sidase pairs are representative examples,230 but many other
therapies could benefit from this concept. Thus, GlcNAc-coated
nanoparticles having a hard metal core such as quantum dots or
gold nanoparticles and a soft shell, namely nanosomes (NSs),
were recently found to be efficiently internalized by human
hepatocarcinoma HepG2 cells in vitro, probably through lectin-
mediated endocytosis.224 NSs bearing a multivalent presentation
of a GlcNAc-based suicide inhibitor additionally inhibited very
competently lysosomal b-hexosaminidase, which is a promising
target that induces a lysosomal membrane permeabilization
(LMP)-mediated cell death pathway. This can be seen as an
example of self-deliverable anticancer therapeutic nanomedicine
benefiting from multivalent enzyme inhibition, a notion that
deserves to be explored.
Fig. 14 Structures of the mannosyl-coated heptavalent and decahexavalent
glycoclusters built on b-cyclodextrin (highlighted in yellow) and RAFT cyclo-
peptide (highlighted in orange), reported by Garcı́a Fernández, Renaudet and
Ortiz Mellet, with the ability to simultaneously and distinctly target the MMR
and the LSD-associated glycosidases b-glucocerebrosidase (GCase) and
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Advancing the fundamental knowledge of the generalized
multivalent effect will also shed light on other supramolecular
events essential for cell life, e.g. the role of glycoheterogeneity
in the packing processes involving polysaccharides at the
glycocalyx and the extracellular matrix.241 It is pertinent to note
that many of the expressions of the generalized multivalent
effect have a dimensional character; that is, they imply nano-
metric entities and relay on surface contacts, a biomimetic
mechanism. It is then conceivable that other non-carbohydrate
or glycomimetic motifs, or even the own nanoparticle shape
and surface nature,242 could actively influence the supramolecular
chemistry of (hetero)multivalent glycoligands towards both lectins
and enzymes. Multifunctional molecular nanoparticles designed
to simultaneously bind nucleic acids and lectins represent a
particularly interesting case to study in this sense.243–247 Further
outlook includes the conception of hybrid (hetero)glycomaterials
to interrogate the compositional and functional complexities of
the cell surface, which in turn has the potential to lead to
unanticipated advances in precision glyconanotechnology.52,248
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2012, 77, 1273.
90 D. Ponader, P. Maffre, J. Aretz, D. Pussak, N. M. Ninnemann,
S. Schmidt, P. H. Seeberger, C. Rademacher, G. U. Nienhaus and
L. Hartmann, J. Am. Chem. Soc., 2014, 136, 2008.
91 S. A. Hill, C. Gerke and L. Hartman, Chem. – Asian J., 2018, 13, 3611.
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Biophys. Acta, Mol. Basis Dis., 2016, 1862, 1663.
208 N. Gueder, G. Allan, M.-S. Telliez, F. Hague, J. M. Garcı́a Fernández,
E. M. Sánchez-Fernández, C. Ortiz Mellet, A. Ahidouch and
H. Ouadid-Ahidouch, J. Cell. Physiol., 2017, 232, 3631.
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